Antidepressant use and risk of adverse outcomes in older people: population based cohort study by Coupland, Carol et al.
Antidepressant use and risk of adverse outcomes in
older people: population based cohort study
Carol Coupland associate professor in medical statistics
1, Paula Dhiman research statistician
1,
Richard Morriss professor of psychiatry and community mental health
2, Antony Arthur associate
professor in elder care
3, Garry Barton senior lecturer in health economics
4, Julia Hippisley-Cox
professor of clinical epidemiology and general practice
1
1Division of Primary Care, University of Nottingham, Nottingham NG7 2RD, UK;
2Division of Psychiatry, University of Nottingham;
3Division of
Nursing, University of Nottingham;
4Health Economics Group (HEG), School of Medicine, Health Policy and Practice, University of East Anglia,
Norwich, UK
Abstract
Objectives To investigate the association between antidepressant
treatment and risk of several potential adverse outcomes in older people
with depression and to examine risks by class of antidepressant, duration
of use, and dose.
Design Cohort study of people aged 65 and over diagnosed as having
depression.
Setting 570 general practices in the United Kingdom supplying data to
the QResearch primary care database.
Participants 60 746 patients diagnosed as having a new episode of
depression between the ages of 65 and 100 years from 1 January 1996
to 31 December 2007 and followed up until 31 December 2008.
Main outcome measures Hazard ratios associated with antidepressant
use for all cause mortality, attempted suicide/self harm, myocardial
infarction, stroke/transient ischaemic attack, falls, fractures, upper
gastrointestinal bleeding, epilepsy/seizures, road traffic accidents,
adverse drug reactions, and hyponatraemia, adjusted for a range of
potential confounding variables. Hazard ratios were calculated for
antidepressant class (tricyclic and related antidepressants, selective
serotonin reuptake inhibitors, other antidepressants), dose, and duration
of use and for commonly prescribed individual drugs.
Results 54 038 (89.0%) patients received at least one prescription for
an antidepressant during follow-up. A total of 1 398 359 antidepressant
prescriptions were issued: 764 659 (54.7%) for selective serotonin
reuptake inhibitors, 442 192 (31.6%) for tricyclic antidepressants, 2203
(0.2%) for monoamine oxidase inhibitors, and 189 305 (13.5%) for the
group of other antidepressants. The associations with the adverse
outcomes differed significantly between the antidepressant classes for
seven outcomes. Selective serotonin reuptake inhibitors were associated
with the highest adjusted hazard ratios for falls (1.66, 95% confidence
interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared
with when antidepressants were not being used. The group of other
antidepressants was associated with the highest adjusted hazard ratios
for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm
(5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to
1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to
3.15), compared with when antidepressants were not being used.
Tricyclic antidepressants did not have the highest hazard ratio for any
of the outcomes. Significantly different associations also existed between
the individual drugs for the same seven outcomes; trazodone (tricyclic
antidepressant), mirtazapine, and venlafaxine (both in the group of other
antidepressants) were associated with the highest rates for some of
these outcomes. Absolute risks over 1 year for all cause mortality were
7.04% for patients while not taking antidepressants, 8.12% for those
taking tricyclic antidepressants, 10.61% for selective serotonin reuptake
inhibitors, and 11.43% for other antidepressants.
Conclusions Selective serotonin reuptake inhibitors and drugs in the
group of other antidepressants were associated with an increased risk
of several adverse outcomes compared with tricyclic antidepressants.
Among individual drugs, trazodone, mirtazapine, and venlafaxine were
associated with the highest risks for some outcomes. As this is an
observational study, it is susceptible to confounding by indication,
channelling bias, and residual confounding, so differences in
characteristics between patients prescribed different antidepressant
drugs that could account for some of the associations between the drugs
and the adverse outcomes may remain. Further research is needed to
confirm these findings, but the risks and benefits of different
antidepressants should be carefully evaluated when these drugs are
prescribed to older people.
Introduction
Depression is a common condition in older people, affecting
around10-15%ofthoselivinginthecommunity.
1 2IntheUnited
Kingdom, depression is largely treated in primary care with
antidepressant drugs. Antidepressants are one of the most
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RESEARCHcommonly prescribed drug groups in primary care. Around 39
million prescriptions for antidepressants were issued in the
community in England in 2009 across all ages, an increase of
35% over five years.
3 Prescriptions increased most for the class
ofselectiveserotoninreuptakeinhibitorantidepressants—a47%
increase over five years, compared with an 18% increase for
the class of tricyclic and related antidepressants and a 37%
increase for other antidepressants.
4 5 A systematic review in
older people found that tricyclic antidepressants and selective
serotoninreuptakeinhibitorswereequivalentintermsofefficacy
but that classic tricyclic antidepressants were associated with a
higher discontinuation rate owing to side effects.
6 The National
Institute for Health and Clinical Excellence recommends that
the choice of an antidepressant should be guided by
consideration of side effects and the patient’s preferences but
thatnormallyaselectiveserotoninreuptakeinhibitoringeneric
form should be chosen.
7
Little is known about more serious adverse effects of
antidepressants, particularly in older people, in whom adverse
drugeventsmaybemorecommoninthetreatmentofdepression
compared with younger groups because of higher levels of
comorbidity, age related physiological changes, and
polypharmacy.
8 The under-representation of older people in
clinicaltrialsofantidepressantsandthefactthatmostsuchtrials
areshorttermmakederivingreliableorpreciseestimatesofthe
incidence of adverse events in this group difficult.
9 10 This
problem is further compounded when criteria for trials exclude
older people with comorbid conditions.
11 Although several
observationalstudieshaveexamineddifferentadverseoutcomes
associatedwithuseofantidepressants,
12fewhavebeenspecific
to an older population.
We therefore did a large cohort study of antidepressant use in
older people to investigate the association between
antidepressant treatment and risk of several potential adverse
outcomes. We directly compared antidepressant class effects
and examined dose and associations with use of commonly
prescribed individual drugs. We aimed to derive a
comprehensive and integrated picture of the relative safety and
balance of risks for antidepressant drugs in older people
diagnosed as having depression.
Methods
Full details of the study methods are published in a Health
TechnologyAssessmentmonograph.
13Wereportthekeyfindings
of the study here, and further results are presented in the full
report.
Setting
In summary, we used the QResearch primary care research
database (version 22) to do a cohort study in a large population
of primary care patients. Practices that provide data for
QResearchusetheEgtonMedicalInformationSystems(EMIS)
medical records system. EMIS is the major supplier of primary
care computer systems in the UK and is in use in around two
thirds of UK general practices. The practices that contribute
data to QResearch are spread throughout the UK and comprise
around 7% of all UK general practices. A comparison of
QResearch practices with all UK practices found that practices
contributing to QResearch tended to be marginally larger than
UK practices overall but were similar in other respects.
14 The
databaseincludesdataonpatients’demographics,consultations,
symptoms, diagnoses (including diagnoses made in secondary
care obtained from hospital discharge letters), referrals, results
of investigations, and prescribed drugs.
Study cohort
The target population for the cohort study was all patients in
theQResearchdatabasewitharecordeddiagnosisofdepression
made when they were aged 65 and over and between 1 January
1996 and 31 December 2007. We used the first such diagnosis
as the index diagnosis. We used computer recorded Read codes
to identify a diagnosis of depression, using case definitions
similar to those that have been used in previous studies.
15 16
Patientswithapreviousrecordeddiagnosisofdepressionbefore
the age of 65 were eligible for inclusion in the study to increase
therepresentativenessofthestudycohort.Weexcludedpatients
if any of the following applied: they were aged 100 years or
more at diagnosis; the diagnosis occurred less than 12 months
after registration with a study practice or after the installation
date of the practice’s EMIS computer system; they were
temporary residents; they had a diagnosis of depression in the
12 months before their index recorded diagnosis of depression;
theyhadbeenprescribedantidepressantsinthe12monthsbefore
their recorded diagnosis of depression; or they had a diagnosis
of schizophrenia, bipolar disorder, or other types of psychoses.
We defined the date of entry in the study for each patient as the
date of the first recorded diagnosis of depression after age 65
within the study period or the date of the first prescription for
an antidepressant after age 65 if that occurred before the
recorded date of depression.
Outcome data
We followed the cohort until 31 December 2008. We extracted
information on adverse outcomes during follow-up from the
primarycarecomputerrecordsonthebasisofcomputerrecorded
Read codes (which include diagnoses made in primary and
secondary care) and also from the linked death certificates by
using ICD-9 (international classification of diseases, 9th
revision) and ICD-10 codes if patients had died during the
follow-up period. We included outcomes only if they occurred
after the study entry date and up to 31 December 2008. The
pre-specified outcomes were all cause mortality, attempted
suicide/self harm, myocardial infarction, stroke/transient
ischaemic attack, falls, fractures (upper limb, lower limb, ribs,
skull, vertebrae, pelvis), upper gastrointestinal bleeding,
epilepsy/seizures,roadtrafficaccidents,adversedrugreactions
(including bullous eruption), and hyponatraemia.
Three other pre-specified outcomes were sudden cardiac death,
suicide(includingopenverdicts),andoverdose/poisoningfrom
antidepressants,butthenumbersofpatientsidentifiedwiththese
outcomes were small, which limited the analyses that could be
done.Wedidanadditionalanalysisusingstrokeasanoutcome,
excluding transient ischaemic attacks.
Exposure data
The primary exposure of interest was treatment with
antidepressantdrugs.Weextractedinformationonallindividual
prescriptions for antidepressants during follow-up, including
detailed information on the drug name and formulation, dosage
instructions,andnumbersoftabletsissuedforeachprescription.
We grouped antidepressant drugs for analysis according to the
major classes of antidepressants as described in the British
National Formulary
17: tricyclic and related antidepressants,
monoamine oxidase inhibitors, selective serotonin reuptake
inhibitors, and other antidepressants.
Some patients received prescriptions for different drugs within
a class or drugs from different classes on the same date. We
classifiedtheseprescriptionsascombinedprescriptionsforsome
analyses (results not presented but available from the authors).
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RESEARCHWe determined the duration of each prescription in days by
dividing the number of tablets prescribed by the dosing
directions(forexample,numberoftabletstobetakeneachday).
To calculate the daily dose of each prescription, we multiplied
the specified dose of each tablet prescribed by the number of
tablets to be taken each day, where this could be evaluated. To
enablecomparisonofdosesbetweentheantidepressantclasses,
weconverteddailydosetoadefineddailydose,byusingvalues
assigned by the World Health Organization’s Collaborating
Centre for Drug Statistics Methodology (www.whocc.no/atc_
ddd_index).
Confounding variables
The potential confounding variables included in the analysis
were age at study entry date; sex (male, female); year of
diagnosis of depression; previous recorded diagnosis of
depression before age 65; severity of index diagnosis of
depression(categorisedasmild,moderate,orsevereonthebasis
of the Read code for the index diagnosis, using codes for each
category published by Martinez and colleagues,
16 and some
classification by a member of the study team (RM) for Read
codesfordepressionnotincludedinthepublishedlist;theRead
codes and their severity categorisation are given in the web
appendix); deprivation, based on Townsend deprivation score
for the patient’s postcode,
18 categorised into fifths according to
theoverallQResearchpopulation;smokingstatus(non-smoker,
ex-smoker,currentsmoker);comorbiditiesatbaseline(coronary
heartdisease,diabetes,hypertension,stroke/transientischaemic
attack,cancer,dementia,epilepsy/seizures,Parkinson’sdisease,
hypothyroidism, obsessive-compulsive disorder, identified by
usingappropriatecomputerrecordedReadcodesinthepatients’
records); use of other drugs at baseline (statins, non-steroidal
anti-inflammatory drugs, antipsychotics, lithium, aspirin,
antihypertensivedrugs,anticonvulsants,hypnotics/anxiolytics);
and previous falls before baseline (for the analysis of fracture).
Statistical analysis
We used Cox’s proportion hazards models to do separate
analyses for each outcome. We used time to the first recorded
diagnosisofeachoutcomeintheanalysesandexcludedpatients
whoalreadyhadtheoutcomerecordedatbaseline.Wecensored
patients who did not have the outcome of interest during
follow-up at the earliest of date of death, date of leaving the
practice, date of the latest download of data, or the study end
date (31 December 2008). We treated antidepressant use as a
timevaryingexposuretoaccountforpatientsstoppingtreatment
and changing between treatments during follow-up. For the
mainanalyses,weconsideredpatientstobeexposedtotreatment
if no gaps of more than 90 days existed between the end of one
prescription and the start of the next.
The analysis calculated hazard ratios and 95% confidence
intervals for antidepressant treatment, both unadjusted and
adjustedforthepotentialconfoundingvariablesdescribedabove,
excluding patients with missing values for smoking status or
deprivation. The main analyses examined use of each class of
antidepressants(selectiveserotoninreuptakeinhibitors,tricyclic
antidepressants, and other antidepressants) compared with no
currenttreatmentandalsodirectlycomparedselectiveserotonin
reuptake inhibitors and the group of other antidepressants with
tricyclic antidepressants. We did analyses for antidepressant
dose, categorising dose for each antidepressant class into three
categories (≤0.5 defined daily doses, >0.5 and ≤1.0 defined
dailydoses,and>1.0defineddailydoses).Wedidtestsoftrend
usingcontinuousdoseindefineddailydosesforeachclass.We
examineddurationoftreatmentasatimevaryingexposurebased
on time since starting antidepressant treatment and time since
stopping treatment categorised for each antidepressant class as
no use, 1-28 days’ use, 29-84 days’ use, and 85 or more days’
useandperiodsof1-28days,29-84days,and85-182daysafter
stopping treatment. We compared use of individual
antidepressant drugs with no current treatment when numbers
weresufficient.Weexcludedpatientswhohadtakenmonoamine
oxidase inhibitors at any time during follow-up from these
analyses, as numbers were too small to allow precise estimates
to be made.
We used a P value of <0.01 (two tailed) to assess statistical
significance. We did Wald’s significance tests to determine
whether the categorical variable for antidepressant class was
significant overall and to test for equality of effects of the
differentclasses,excludingthecategoryofnocurrenttreatment,
to determine whether significant differences existed between
theclasses.Wealsodidthisfortheanalysesofindividualdrugs.
We assessed whether the assumption of proportional hazards
was valid graphically. We used Stata (v10.1) for all analyses.
We estimated absolute risks for each outcome at one year from
the index date, firstly in patients while they were not taking
antidepressant treatment and then combining this with the
adjusted hazard ratios for antidepressant class and individual
drugs to calculate adjusted absolute risks in the treated groups
byusingapublishedformula.
19Weincludedalleligiblepatients
in the database in our analyses to maximise power.
Results
A total of 88 701 patients in the QResearch database had a
recordeddiagnosisofdepressionmadeattheageof65andover
between 1 January 1996 and 31 December 2007. After we
consecutively excluded 22 patients aged 100 and over at
diagnosis, 3178 patients with schizophrenia, bipolar disorder,
or other psychoses, 15 690 who had joined the practice in the
previous year, and 9065 with a diagnosis of depression or a
prescription for an antidepressant in the previous year, 60 746
eligible patients remained. These patients were from 570
QResearch practices, including 543 in England, 14 in Wales,
four in Scotland, and nine in Northern Ireland.
Table 1 shows baseline characteristics of the study cohort. The
mean age of the study cohort was 75.0 years, and the cohort
contained 20 230 (33.3%) men and 40 516 (66.7%) women.
The total number of person years of follow-up was 305 188,
with a mean of 5.0 (SD 3.3) years per patient.
Patterns of antidepressant treatment
Duringfollow-up,54038(89.0%)patientsreceivedatleastone
prescription for an antidepressant drug, and a total of 1 398 359
prescriptions for antidepressants were issued. A total of 6484
(10.7% of 60 746) patients had only a single prescription for an
antidepressant, and 6624 (10.9%) received 60 prescriptions or
more during follow-up. The median duration of treatment with
antidepressants during follow-up was 364 (interquartile range
91-1029) days.
Selectiveserotoninreuptakeinhibitorswerethemostcommonly
prescribed drug class, comprising 54.7% (764 659) of the total
antidepressant prescriptions. Patients received 442 192 (31.6%
of all antidepressant prescriptions) prescriptions for tricyclic
antidepressants and 189 305 (13.5%) for the group of other
antidepressants. Monoamine oxidase inhibitor drugs were the
least commonly prescribed class, comprising only 0.2% (2203
prescriptions) of the total prescriptions issued. Because of the
smallnumberofprescriptionsformonoamineoxidaseinhibitors,
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RESEARCHwe excluded patients prescribed these drugs from further
analysis. Table 2 shows the prescribed doses by antidepressant
class for the prescriptions where this could be evaluated. Doses
tended to be lowest for tricyclic antidepressants—70.0% of
prescriptionswerefor≤0.5defineddailydoses,comparedwith
13.8%forselectiveserotoninreuptakeinhibitorsand19.2%for
the group of other antidepressants.
The 10 most commonly prescribed antidepressant drugs
(citalopram hydrobromide (selective serotonin reuptake
inhibitor),fluoxetinehydrochloride(selectiveserotoninreuptake
inhibitor),amitriptylinehydrochloride(tricyclicantidepressant),
dosulepin hydrochloride (tricyclic antidepressant), paroxetine
hydrochloride (selective serotonin reuptake inhibitor),
venlafaxine hydrochloride (other), sertraline hydrochloride
(selective serotonin reuptake inhibitor), mirtazapine (other),
lofepramine (tricyclic antidepressant), and escitalopram
(selectiveserotoninreuptakeinhibitor))comprised93.6%(n=1
309 056) of all antidepressant prescriptions. As only slightly
fewer prescriptions for trazodone hydrochloride (tricyclic
antidepressant) were issued, we considered the 11 most
commonly prescribed drugs, comprising 96.0% (n=1 342 731)
of all prescriptions, separately in some analyses (fig 1).
Results of analyses by antidepressant class
Tables3and4showtheresultsoftheanalysisbyantidepressant
class. All classes of antidepressant drug were associated with
significantly increased risks of all cause mortality, attempted
suicide/self harm, falls, fractures, and upper gastrointestinal
bleeding compared with when these drugs were not being used.
Selective serotonin reuptake inhibitors and the group of other
antidepressant drugs were associated with increased risks of
stroke/transientischaemicattackandepilepsy/seizures;selective
serotoninreuptakeinhibitorswerealsoassociatedwithincreased
risks of myocardial infarction and hyponatraemia.
The associations with the adverse outcomes differed
significantly between the classes of antidepressant drugs for
sevenoutcomes:allcausemortality,attemptedsuicide/selfharm,
stroke/transient ischaemic attack, falls, fracture,
epilepsy/seizures,andhyponatraemia.Fortheseoutcomes,when
compared directly with tricyclic antidepressants, selective
serotoninreuptakeinhibitorswereassociatedwithsignificantly
higher rates of all cause mortality (adjusted hazard ratio 1.32,
95%confidenceinterval1.26to1.39),stroke/transientischaemic
attack (1.15, 1.05 to 1.26), falls (1.27, 1.20 to 1.35), fracture
(1.26, 1.15 to 1.37), epilepsy/seizures (1.80, 1.32 to 2.43), and
hyponatraemia (1.44, 1.19 to 1.75). We found no significant
difference for attempted suicide/self harm (1.27, 0.97 to 1.66).
Thegroupofotherantidepressantshadsignificantlyhigherrates
compared with tricyclic antidepressants for all cause mortality
(adjustedhazardratio1.43,1.33to1.54),attemptedsuicide/self
harm (3.04, 2.21 to 4.17), stroke/transient ischaemic attack
(1.35, 1.18 to 1.54), fracture (1.31, 1.15 to 1.50), and
epilepsy/seizures (2.20, 1.46 to 3.30). We found no significant
difference for falls (1.07, 0.97 to 1.17) or hyponatraemia (1.21,
0.90to1.64).Tricyclicantidepressantswerenotassociatedwith
significantlyhigherratesofanyoftheoutcomeswhencompared
withselectiveserotoninreuptakeinhibitorsorthegroupofother
antidepressants.
We found similar results in an additional analysis that included
only strokes as an outcome rather than strokes and transient
ischaemic attacks. For example, the adjusted hazard ratio was
1.05 (0.95 to 1.17) for tricyclic antidepressants, 1.21 (1.11 to
1.32) for selective serotonin reuptake inhibitors, and 1.44 (1.24
to 1.67) for other antidepressants, all compared with when
antidepressants were not being used.
The proportional hazards assumption of the Cox proportional
hazards model was reasonable for most outcomes, although we
found some indication of convergence for stroke/transient
ischaemic attack, upper gastrointestinal bleeding, and
hyponatraemia towards the end of the follow-up period.
Results of analyses for individual
antidepressant drugs
Figure 2 shows adjusted hazard ratios associated with the 11
most commonly prescribed individual drugs. We found
significantdifferencesbetweentheassociationswiththesedrugs
(P<0.01) for all cause mortality, attempted suicide/self harm,
stroke/transient ischaemic attack, falls, fracture,
epilepsy/seizures, and hyponatraemia.
Trazodone (a tricyclic antidepressant) was associated with the
highest adjusted hazard ratio for all cause mortality and one of
the highest hazard ratios for attempted suicide/self harm.
Mirtazapine (in the group of other antidepressants) was
associated with the highest adjusted hazard ratio for attempted
suicide/self harm and one of the highest for all cause mortality
andstroke/transientischaemicattack.Venlafaxine(inthegroup
of other antidepressants) was associated with higher adjusted
hazard ratios for stroke/transient ischaemic attack,fracture, and
epilepsy/seizuresthantheotherdrugsandwithoneofthehighest
for all cause mortality and attempted suicide/self harm.
Citalopram (a selective serotonin reuptake inhibitor) was
associated with the highest adjusted hazard ratio for falls, but
risks were similar for all of the selective serotonin reuptake
inhibitors.
Three selective serotonin reuptake inhibitors (citalopram,
escitalopram,andfluoxetine)wereassociatedwithsignificantly
increased risks of hyponatraemia, but paroxetine and sertraline
werenot.Wefoundsomeevidenceofincreasedratesofadverse
drug reactions associated with lofepramine and sertraline.
Amitriptylineanddosulepin(bothtricyclicantidepressants)had
the lowest risks for many of these outcomes.
We found similar results in an additional analysis that only
includedstrokesasanoutcomeratherthanstrokesandtransient
ischaemic attack, except for a higher hazard ratio associated
with trazodone (adjusted hazard ratio 1.48, 1.08 to 2.04)
compared with when antidepressants were not being used.
Analyses by dose and duration
We found significant trends (at P<0.01) with dose of tricyclic
antidepressants and selective serotonin reuptake inhibitors for
all cause mortality, falls, and epilepsy/seizures. We also found
a significant dose-response relation between dose of tricyclic
antidepressants and fracture (see web extra table A). For most
outcomes, risks were highest in the first 28 days of use and also
in the first 28 days after stopping antidepressant treatment (see
web extra table B).
Absolute risks
Table5showsabsoluterisksatoneyearbyantidepressantclass
and individual drug for each of the adverse outcomes. The
absolute risks were highest for all cause mortality,
stroke/transient ischaemic attack, falls, and fracture. Absolute
risks for all cause mortality over one year were 7.04% for
patientswhilenottakingantidepressants,8.12%forthosetaking
tricyclicantidepressants,10.61%forselectiveserotoninreuptake
inhibitors, and 11.43% for other antidepressants.
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RESEARCHDiscussion
Thisobservationalstudyfoundsignificantassociationsbetween
useofantidepressantdrugsandseveralsevereadverseoutcomes
in people aged 65 and older with depression. We found no
evidence that use of selective serotonin reuptake inhibitors or
drugsinthegroupofotherantidepressantswereassociatedwith
a reduced risk of any of the adverse outcomes compared with
tricyclic antidepressants. However, compared with tricyclic
antidepressants, selective serotonin reuptake inhibitors may be
associatedwithanincreasedriskofcertainoutcomes,including
all cause mortality, stroke/transient ischaemic attack, falls,
fracture, epilepsy/seizures, and hyponatraemia, and the group
of other antidepressants may be associated with an increased
risk of all cause mortality, attempted suicide/self harm,
stroke/transientischaemicattack,fracture,andepilepsy/seizures.
Examination of individual drugs found that trazodone,
mirtazapine, and venlafaxine were associated with the highest
rates for some outcomes. To our knowledge, this is the first
published systematic assessment of the safety of commonly
used antidepressants in older patients across a range of serious
adverse outcomes.
Possible explanations for findings
Tricyclic antidepressants were prescribed at lower doses than
were selective serotonin reuptake inhibitors and other
antidepressant drugs, which could in part explain our findings.
However, within separate categories of dose, tricyclic
antidepressantsstilltendedtobeassociatedwithloweradjusted
hazardratiosforallcausemortality,attemptedsuicide/selfharm,
stroke/transient ischaemic attack and epilepsy/seizures within
each dose category. Also, this reflects prescribing patterns in
primary care, and some evidence shows that low dose tricyclic
antidepressants are similar to higher dose tricyclics in terms of
reducing symptoms of depression.
7 20
Rates of most outcomes were highest in the first 28 days after
starting an antidepressant, and also in the first 28 days after
stopping. For all cause mortality, myocardial infarction,
stroke/transient ischaemic attack, adverse drug reactions, and
hyponatraemia,wefoundsomeevidencethatrateswerereduced
after 85 days of use. Changes in the severity of depression,
particularlyafterstartingantidepressanttreatment,couldexplain
why increases in rates of adverse events were generally most
marked in the first 28 days after a prescription, when the
depression is likely to be more severe, and could also explain
the reductions in rates for some outcomes after 85 days of use
whenthedepressionmayberesolving.Thiswillhavelesseffect
on direct comparisons between antidepressant classes or
individual drugs than on comparisons with non-use of
antidepressants. The increased rates after stopping treatment
may reflect patients stopping the drugs because of an onset of
illness or after being admitted to hospital or a residential home,
and increased rates of adverse events may be associated with
these factors rather than being a direct effect of withdrawal.
Strengths and limitations
This was a large population based study with broad inclusion
criteria, so the findings are generalisable to the population of
older people diagnosed as having depression in primary care.
Thisisincontrastwithclinicaltrials,whichgenerallyhavestrict
inclusionandexclusioncriteria,tendingtoleadtotheexclusion
of many older people who have comorbidities or are taking
drugs for other conditions. In addition, we included all eligible
patients, which reduced selection bias. The study size enabled
us to detect associations with relatively rare adverse events.
The data were recorded prospectively, so all information on
prescriptions for antidepressants and potential confounding
variables was recorded before the occurrence of an adverse
outcome, meaning that recall bias will not have occurred. We
adjusted our analyses for several potential confounding
variables, including comorbidities and use of other drugs.
Wehaddetailedinformationonprescriptionsforantidepressants
issued in primary care throughout the follow-up period, so we
could do comprehensive analyses investigating effects of
individual drugs, dose, and duration. This contrasts with many
cohort or case-control studies in which information on
antidepressant use is self reported or collected only at the start
of the study.
The main concern with observational studies such as this one
is indication bias. Indication bias occurs when patients are
prescribed drugs for a condition that is itself associated with
the outcome of interest. This means that apparent associations
with a drug may be due to the condition for which it was
prescribed rather than to the drug itself. To reduce this bias, we
restricted our study cohort to include only patients with a
recorded diagnosis of depression, so that all patients, whether
treated or not, had the same indication for treatment. This is
important, as depression itself is associated with many adverse
outcomes.
21-23 Some systematic differences are still likely
between patients who are treated and those who are not. Those
whoarenottreatedarelikelytohavelessseveredepressionand
may have poorer physical health, such that they are considered
too frail for antidepressant treatment. We adjusted for many
factors that could differ between groups, including age, sex,
severity of depression, several comorbidities, and use of other
drugs. Generally, the adjustment did not have a large effect on
the results. However, although we adjusted for severity of the
initial diagnosis of depression, we could use only a crude
measure as we did not have a validated depression severity
score.Wecannotthereforeexcludethepossibleeffectofresidual
confounding on our results.
Direct comparisons between treated groups are less susceptible
to confounding by indication, or confounding due to factors
influencing prescribing of treatment, but are still subject to
channelling bias, whereby different antidepressant drugs with
similar indications might be prescribed according to varying
characteristics of patients. An example of this would be the
preferentialprescribingofselectiveserotoninreuptakeinhibitors
rather than tricyclic antidepressants to frail patients at greater
risk of falling.
24 Again, adjusting for a range of potential
confounding factors would be expected to reduce the effect of
this bias; for example, in the analysis of fracture we adjusted
for falls at baseline as well as for many other confounders. This
bias would also be less likely to apply to comparisons between
individual drugs within a class than to comparisons between
classes.
Residual confounding may remain in the findings, as certain
potential confounding variables may not be recorded on the
database or may not be recorded in sufficient detail to
completelyremovetheirconfoundingeffect.Asasupplementary
analysis, we did a self controlled case series analysis. This is a
withinpatientscomparison,whichimplicitlyremovestheeffects
of all characteristics that vary between patients, irrespective of
whether or in how much detail they have been recorded on the
database, assuming that they do not vary over time within the
observation period.
25 The results from the case series analyses
were generally consistent with the cohort analyses, although
the risks for attempted suicide/self harm for the group of other
antidepressantswerelower.
13Theseanalyses,however,arealso
susceptible to confounding from time varying factors. We
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RESEARCHcannot, therefore, exclude the possible effect of residual
confounding for these results.
We did not specifically validate our outcomes as part of this
study. However, reviews of validation studies in other UK
primary care databases have shown overall high levels of
validity, and we would expect similar levels of validity in
QResearch.
26 27 For example, Khan reported that particularly
high (>90%) proportions of cases recorded in the general
practice record were confirmed when further information was
obtainedforseveraloutcomesincludingcerebrovasculardisease,
hipfracture,anduppergastrointestinalbleeding.
27Weincluded
informationfromdeathcertificatestoidentifyadditionalpatients
with the outcomes, which will have reduced misclassification.
We have assessed only potential adverse effects of
antidepressants in this study and not potential benefits, as very
limited data are available for evaluating effectiveness of the
different antidepressants in the QResearch database.
Comparison with other studies
Several observational studies have examined the effects of
antidepressant drugs on single adverse outcomes, although few
have been done specifically in older people or have examined
them as a subgroup and few, if any, studies have directly
comparedadverseeventratesacrossarangeofimportantclinical
outcomes. These studies have identified several adverse
outcomes that may be associated with antidepressants, but an
intrinsic problem with observational studies of antidepressants
is the difficulty of distinguishing between the effects of
antidepressant drugs and depression itself.
Attempted suicide/self harm
Relatively few studies have looked at antidepressants and
attempted suicide/self harm in older people. A meta-analysis
ofrandomisedcontrolledtrialsregisteredwiththeUSFoodand
DrugAdministrationfoundareducedriskofsuicidalbehaviour
and ideation associated with antidepressants in the group aged
65yearsandover.
28Itfoundnoevidenceofadifferencebetween
drug classes across people of all ages. A systematic review of
observational studies also found a reduction in risk of suicide
or attempted suicide associated with use of selective serotonin
reuptake inhibitors in the subgroup aged 65 years and older.
29
Little evidence supports or refutes our findings of increased
rates associated with mirtazapine, venlafaxine, and trazodone
compared with other antidepressants, and these warrant further
investigation.
Myocardial infarction and stroke
The literature contains no clear findings for risk of myocardial
infarction and antidepressant use in older people. Some studies
havefoundanincreasedriskofmyocardialinfarctionassociated
with antidepressant use,
30-33 some have found a protective
effect,
34-36 and others have found no association.
37 An increased
risk has been observed as being restricted to tricyclic
antidepressants or selective serotonin reuptake inhibitors,
32 33
applying across classes,
30 31 or restricted to particular drugs.
15
Evidence of a protective effect is largely limited to selective
serotonin reuptake inhibitors.
34 35
Findings from previous studies of antidepressants and risk of
strokeareinconsistent,butsomestudieshavefound(aswedid)
a possible increase in risk among users of selective serotonin
reuptake inhibitors and the group of other antidepressants.
37 38
If selective serotonin reuptake inhibitors have an effect on
occurrence of stroke, this may result from an increased risk of
bleeding complications, as these drugs limit uptake of blood
serotonin by platelets, which leads to inhibition of platelet
aggregation, thereby preventing haemostasis by platelets.
39 40
This mechanism could explain an association specifically with
haemorrhagic stroke, but we were not able to distinguish
between ischaemic and haemorrhagic stroke in this study.
Falls and fracture
A review of 78 studies found that the effects of tricyclic
antidepressants and selective serotonin reuptake inhibitors on
the risk of falls were generally similar across studies; few data
were available for other antidepressants.
41 Two studies
specifically in older patients found that selective serotonin
reuptake inhibitors in particular were strongly associated with
the risk of falls.
42 43 A cohort study of patients aged 60 and over
foundthatselectiveserotoninreuptakeinhibitorswereassociated
with a more than twofold increase in the risk of falls but found
nosignificantincreaseforotherantidepressants.
44Findingsfrom
theliteraturesuggestthatselectiveserotoninreuptakeinhibitors
and tricyclic antidepressants are associated with increased
fracture rates,
24 45-47 with possibly somewhat higher rates for
selective serotonin reuptake inhibitors than for tricyclic
antidepressants.
45-47 Little evidence exists for other
antidepressants. Our findings of a more marked and prolonged
increase in risk for selective serotonin reuptake inhibitors
comparedwithtricyclicantidepressantsareingeneralagreement
with this. The increased risk of fracture associated with
antidepressant use may be due to an increased risk of falls, but
someevidencealsoshowsreducedbonemineraldensityinusers
of selective serotonin reuptake inhibitors.
48 49
Gastrointestinal bleeding
Gastrointestinal bleeding has been found in some studies to be
more common among patients taking selective serotonin
reuptakeinhibitors,
50 51includingthoseaged65yearsandover.
52
Aproposedmechanismforthisfindingisthatthesedrugsblock
serotonin reuptake by platelets, leading to impairment of the
platelethaemostaticresponse.
53Astudythatadjustedforawide
range of potential confounding factors found a small increased
risk of gastrointestinal bleeding among users of selective
serotoninreuptakeinhibitors,whichiscomparableinmagnitude
to ours, with no association for tricyclic antidepressants.
54 We
found some evidence that venlafaxine is associated with a
particularly increased risk of gastrointestinal bleeding, which
has also been found in other studies.
51 54
Hyponatraemia
Hyponatraemiaassociatedwithantidepressantuseisanadverse
event that disproportionately affects older people.
55 56 Studies
haveshownthathyponatraemiaisassociatedmoststronglywith
use of selective serotonin reuptake inhibitors,
56-58 and our
findings are in accordance with that. In these studies,
hyponatraemiadevelopedwithinthefirstfewweeksoftreatment
and resolved within a few weeks after treatment was
discontinued. These cases are thought to be almost entirely due
to the development of the syndrome of inappropriate secretion
of antidiuretic hormone, preventing the reabsorption of water
and sodium ions in the distal tubule of the kidney precipitated
by selective serotonin reuptake inhibitors.
58 59
Other outcomes
Otheroutcomesforwhichsomeevidenceofanassociationwith
antidepressant use exists include all cause mortality,
60 61
seizures,
62roadtrafficaccidents,
63 64andadversedrugreactions,
65
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RESEARCHbut results are not consistent and evidence in older people with
which to compare our findings is lacking.
Clinical implications and future research
Some of our findings are unexpected—in particular, that
contrarytoexpectationstricyclicantidepressantsseemtobethe
safest class of antidepressant in older people for the adverse
outcomes considered in this study. Tricyclic antidepressants
were prescribed at lower doses than the other drugs, but some
evidence shows that low dose tricyclic antidepressants are
similar to higher dose tricyclics in reducing symptoms of
depression.
7 20 Little evidence exists as to whether low dose
tricyclicantidepressantsareasefficaciousasselectiveserotonin
reuptake inhibitors at higher doses in the treatment of
depression; in addition, tricyclic antidepressants may be
associatedwithhigherdiscontinuationratesowingtosideeffects
suchassedationanddrymouth.
6Thepotentialrisksandbenefits
ofdifferentantidepressantsthereforeneedcarefulconsideration
when these drugs are prescribed to older people.
Further research is needed to confirm our findings. Few
randomised trials of antidepressants have been done in older
people, in a primary care setting, with sufficient size and length
of follow-up to assess adverse outcomes as well as benefits, so
a long term randomised trial of antidepressants in older people
with depression in primary care is needed to compare benefits
and risks of more common adverse events between a selective
serotonin reuptake inhibitor and a low dose tricyclic
antidepressant. Research is also needed to confirm our findings
with other data sources of older people in a community setting
and to assess any risks associated with switching between
antidepressant drugs. If our findings are confirmed in other
studies, this would have implications for the selection of
antidepressant treatment in older people, who are already at
higher risk of many of these adverse outcomes.
Conclusions
Thisstudyhasfoundthatselectiveserotoninreuptakeinhibitors
and drugs in the group of other antidepressants were associated
with an increased risk of several adverse outcomes compared
with tricyclic antidepressants. Among the most commonly
prescribed individual drugs, trazodone, mirtazapine, and
venlafaxine were associated with the highest rates for some
outcomes. As this is an observational study, it is susceptible to
confounding by indication, channelling bias, and residual
confounding. Other differences in characteristics may exist
between patients prescribed different antidepressant drugs,
which we have not adjusted for and which may account for
some of the associations between the drugs and the adverse
outcomes.Furtherresearchisneededtoconfirmthesefindings.
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RESEARCHTables
Table 1| Characteristics of study cohort at baseline. Values are numbers (percentages) unless stated otherwise
Study cohort (n=60 746) Characteristic
40 516 (66.7) Female sex
Age group (years):
31 341 (51.6) 65-74
21 497 (35.4) 75-84
7908 (13.0) ≥85
75.0 (7.6) Mean (SD) age (years)
Severity of depression (index diagnosis):
42 281 (69.6) Mild
15 639 (25.7) Moderate
2826 (4.7) Severe
8943 (14.7) Recorded history of depression before age 65
Smoking status:
33 656 (55.4) Non-smoker
13 005 (21.4) Ex-smoker
10 989 (18.1) Smoker
3096 (5.1) Not recorded
(n=59 003) Townsend deprivation score:
12 840 (21.8) Lowest fifth
11 681 (19.8) Second fifth
12 264 (20.8) Third fifth
12 315 (20.9) Fourth fifth
9903 (16.8) Highest fifth
Comorbidities
11 981 (19.7) Coronary heart disease
6169 (10.2) Diabetes
23 654 (38.9) Hypertension
6448 (10.6) Stroke/transient ischaemic attack
5032 (8.3) Any cancer
1091 (1.8) Dementia
953 (1.6) Epilepsy/seizures
869 (1.4) Parkinson’s disease
3956 (6.5) Hypothyroidism
119 (0.2) Obsessive-compulsive disorder
4979 (8.2) Previous falls
Drugs at baseline
1671 (2.8) Anticonvulsants
30 363 (50.0) Antihypertensive drugs
5332 (8.8) Antipsychotics
17 863 (29.4) Aspirin
14 391 (23.7) Hypnotics/anxiolytics
148 (0.2) Lithium
34 618 (57.0) Non-steroidal anti-inflammatory drugs
10 283 (16.9) Statins
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RESEARCHTable 2| Doses prescribed by antidepressant class in defined daily doses*. Values are numbers of prescriptions (column percentages)
Antidepressant class
Defined daily dose (DDD)
prescribed Other Selective serotonin reuptake inhibitors Tricyclic antidepressants
27 912 (19.2) 96 870 (13.8) 250 208 (70.0) ≤0.5 DDD
77 286 (53.2) 505 093 (72.0) 75 922 (21.2) >0.5/≤1 DDD
33 511 (23.1) 25 037 (3.6) 26 139 (7.3) >1/≤1.5 DDD
6664 (4.6) 75 021 (10.7) 5308 (1.5) >1.5 DDD
145 373 702 021 357 577 Total
*Dose prescribed could not be calculated for all prescriptions issued during study period either because dosing directions were not recorded or insufficient detail
was recorded or, for certain drugs, DDD value was not available; doses were combined when patients received more than one prescription with different doses
for same drug on same day.
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RESEARCHTable 3| Hazard ratios for six adverse outcomes (all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient
ischaemic attack, falls, and fractures) by antidepressant class, unadjusted and adjusted for confounders
Hazard ratio (95% CI)
No of events* Antidepressant class Adjusted† Unadjusted
All cause mortality
1.00 1.00 8210 Not taking antidepressants
1.16 (1.10 to 1.22) 0.99 (0.95 to 1.04) 2337 Tricyclic antidepressants
1.54 (1.48 to 1.59) 1.61 (1.55 to 1.66) 5782 Selective serotonin reuptake inhibitors
1.66 (1.56 to 1.77) 1.77 (1.66 to 1.87) 1268 Other antidepressants
17 597/60 640 Total events/total patients
Attempted suicide/self harm
1.00 1.00 150 Not taking antidepressants
1.70 (1.28 to 2.25) 1.67 (1.27 to 2.18) 89 Tricyclic antidepressants
2.16 (1.71 to 2.71) 2.22 (1.77 to 2.78) 178 Selective serotonin reuptake inhibitors
5.16 (3.90 to 6.83) 5.80 (4.41 to 7.63) 79 Other antidepressants
496/59 536 Total events/total patients
Myocardial infarction
1.00 1.00 1264 Not taking antidepressants
1.09 (0.96 to 1.23) 1.02 (0.91 to 1.15) 362 Tricyclic antidepressants
1.15 (1.04 to 1.27) 1.16 (1.05 to 1.27) 614 Selective serotonin reuptake inhibitors
1.04 (0.85 to 1.27) 1.01 (0.83 to 1.23) 110 Other antidepressants
2350/56 428 Total events/total patients
Stroke/transient ischaemic attack
1.00 1.00 2811 Not taking antidepressants
1.02 (0.93 to 1.11) 1.01 (0.93 to 1.10) 791 Tricyclic antidepressants
1.17 (1.10 to 1.26) 1.19 (1.12 to 1.27) 1384 Selective serotonin reuptake inhibitors
1.37 (1.22 to 1.55) 1.35 (1.21 to 1.52) 317 Other antidepressants
5303/54 198 Total events/total patients
Falls
1.00 1.00 5208 Not taking antidepressants
1.30 (1.23 to 1.38) 1.20 (1.14 to 1.27) 1704 Tricyclic antidepressants
1.66 (1.58 to 1.73) 1.71 (1.64 to 1.79) 3575 Selective serotonin reuptake inhibitors
1.39 (1.28 to 1.52) 1.45 (1.34 to 1.58) 631 Other antidepressants
11 118/55 669 Total events/total patients
Fracture
1.00 1.00 2507 Not taking antidepressants
1.26 (1.16 to 1.37) 1.23 (1.13 to 1.33) 809 Tricyclic antidepressants
1.58 (1.48 to 1.68) 1.61 (1.51 to 1.72) 1597 Selective serotonin reuptake inhibitors
1.64 (1.46 to 1.84) 1.64 (1.46 to 1.84) 341 Other antidepressants
5254/52 814 Total events/total patients
*Based on numbers included in unadjusted analyses.
†Adjusted for sex, age (five year bands), year, severity of depression, depression before age 65, smoking status, Townsend deprivation score, coronary heart
disease, diabetes, hypertension, cancer, dementia, Parkinson’s disease, hypothyroidism, obsessive-compulsive disorder, epilepsy/seizures, statins, non-steroidal
anti-inflammatory drugs, antipsychotics, lithium, aspirin, antihypertensive drugs, anticonvulsant drugs, and hypnotics/anxiolytics; all outcomes except stroke/transient
ischaemic attack also adjusted for stroke/transient ischaemic attack at baseline; fracture outcome also adjusted for falls at baseline.
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RESEARCHTable 4| Hazard ratios for five adverse outcomes (upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug
reactions, and hyponatraemia) by antidepressant class, unadjusted and adjusted for confounders
Hazard ratio (95% CI)
No of events* Antidepressant class Adjusted† Unadjusted
Upper gastrointestinal bleeding
1.00 1.00 671 Not taking antidepressants
1.29 (1.10 to 1.51) 1.21 (1.04 to 1.41) 229 Tricyclic antidepressants
1.22 (1.07 to 1.40) 1.27 (1.11 to 1.44) 365 Selective serotonin reuptake inhibitors
1.37 (1.08 to 1.74) 1.36 (1.08 to 1.72) 79 Other antidepressants
1344/59 389 Total events/total patients
Epilepsy/seizures
1.00 1.00 223 Not taking antidepressants
1.02 (0.76 to 1.38) 0.99 (0.74 to 1.32) 58 Tricyclic antidepressants
1.83 (1.49 to 2.26) 1.98 (1.62 to 2.43) 177 Selective serotonin reuptake inhibitors
2.24 (1.60 to 3.15) 2.32 (1.67 to 3.24) 39 Other antidepressants
497/59 691 Total events/total patients in analysis
Road traffic accidents
1.00 1.00 252 Not taking antidepressants
0.86 (0.64 to 1.15) 0.83 (0.62 to 1.11) 56 Tricyclic antidepressants
0.89 (0.70 to 1.13) 0.92 (0.72 to 1.16) 96 Selective serotonin reuptake inhibitors
0.67 (0.39 to 1.14) 0.71 (0.42 to 1.19) 15 Other antidepressants
419/59 678 Total events/total patients
Adverse drug reactions
1.00 1.00 417 Not taking antidepressants
1.06 (0.86 to 1.29) 1.09 (0.89 to 1.32) 139 Tricyclic antidepressants
1.16 (0.98 to 1.37) 1.20 (1.02 to 1.42) 231 Selective serotonin reuptake inhibitors
0.95 (0.68 to 1.34) 1.00 (0.71 to 1.40) 37 Other antidepressants
824/60 170 Total events/total patients
Hyponatraemia
1.00 1.00 503 Not taking antidepressants
1.05 (0.87 to 1.27) 0.99 (0.82 to 1.18) 155 Tricyclic antidepressants
1.52 (1.33 to 1.75) 1.62 (1.42 to 1.86) 383 Selective serotonin reuptake inhibitors
1.28 (0.98 to 1.67) 1.38 (1.06 to 1.80) 62 Other antidepressants
1103/60 300 Total events/total patients
*Based on numbers included in unadjusted analyses.
†Adjusted for sex, age (five year bands), year, severity of depression, depression before age 65, smoking status, Townsend deprivation score, coronary heart
disease, stroke/transient ischaemic attack, diabetes, hypertension, cancer, dementia, Parkinson’s disease, hypothyroidism, obsessive-compulsive disorder, statins,
non-steroidal anti-inflammatory drugs, antipsychotics, lithium, aspirin, antihypertensive drugs, anticonvulsant drugs, hypnotics/anxiolytics; all outcomes except
epilepsy/seizures also adjusted for epilepsy/seizures at baseline.
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RESEARCHTable 5| Absolute risks of adverse outcomes over one year by antidepressant class and top 11 most commonly prescribed antidepressant
drugs
Absolute risks over 1 year (%)
Hyponatraemia
Adverse
drug
reaction RTA Epilepsy/seizures
Upper GI
bleed Fracture Falls Stroke/TIA
Myocardial
infarction
Attempted
suicide/self
harm
All cause
mortality
Antidepressant class
0.29 0.26 0.16 0.21 0.42 1.76 3.46 2.23 1.00 0.25 7.04 Not taking
antidepressants
0.30 0.28 0.13 0.21 0.54 2.18 4.49 2.26 1.09 0.43 8.12 Tricyclic
antidepressants
0.44 0.30 0.14 0.38 0.51 2.74 5.67 2.61 1.15 0.55 10.61 Selective serotonin
reuptake inhibitors
0.37 0.25 0.10 0.46 0.57 2.85 4.79 3.04 1.04 1.30 11.43 Other
antidepressants
Tricyclic antidepressants
0.33 0.25 0.13 0.24 0.58 2.14 4.54 2.24 1.11 0.27 7.72 Amitriptyline
hydrochloride
0.24 0.23 0.08 0.10 0.51 2.15 4.28 2.12 1.07 0.48 7.26 Dosulepin
hydrochloride
0.27 0.55 0.18 0.28 0.51 2.56 4.61 2.79 1.18 0.66 10.43 Lofepramine
0.43 0.27 0.24 0.30 0.75 1.70 5.32 2.45 1.04 1.20 12.44 Trazodone
hydrochloride
Selective serotonin reuptake inhibitors
0.47 0.29 0.16 0.37 0.56 2.83 6.01 2.71 1.11 0.68 10.69 Citalopram
hydrobromide
0.59 0.29 0.15 0.36 0.45 2.26 5.70 2.70 1.32 0.47 10.06 Escitalopram
0.49 0.31 0.11 0.31 0.48 2.76 5.60 2.57 1.31 0.53 11.42 Fluoxetine
hydrochloride
0.30 0.24 0.14 0.42 0.48 2.56 4.97 2.39 1.11 0.29 8.68 Paroxetine
hydrochloride
0.29 0.42 0.14 0.55 0.44 2.80 5.57 2.70 0.89 0.53 10.20 Sertraline
hydrochloride
Other antidepressants
0.31 0.27 0.07 0.33 0.44 2.56 4.11 3.06 1.11 1.56 12.05 Mirtazapine
0.44 0.23 0.11 0.61 0.72 3.26 5.74 3.34 1.05 1.17 11.40 Venlafaxine
hydrochloride
GI=gastrointestinal; RTA=road traffic accident; TIA=transient ischaemic attack.
*Absolute risks for antidepressant drugs adjusted for confounders listed in table 3.
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RESEARCHFigures
Fig 1 Total number of prescriptions during follow-up for 11 most commonly prescribed antidepressant drugs, in total of 54
038 patients. SSRI=selective serotonin reuptake inhibitor; TCA=tricyclic antidepressant
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RESEARCHFig 2 Adjusted (for confounders listed in table 3) hazard ratios (with 95% CI) for outcomes according to 11 most commonly
prescribed antidepressant drugs. GI=gastrointestinal; SSRI=selective serotonin reuptake inhibitor; TCA=tricyclic
antidepressant; TIA=transient ischaemic attack
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RESEARCH